Polymeric Drug Conjugates with Modular Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted drug conjugates, particularly antibody-drug conjugates (ADCs), face challenges due to the complexity of their chemical linkers, leading to difficulties in developing effective therapeutics. There is a need for potent, targeting drug conjugates with a large therapeutic index that can selectively deliver drugs to diseased tissues like tumor cells while minimizing side effects.
Innovation Solution
The development of dimeric and polymeric biologically active compounds with spacing groups, which can be used as targeted drug conjugates. These compounds include biologically active moieties covalently linked by a linker, allowing for selective delivery to targets such as tumor cells. They can be incorporated during polymer synthesis or attached post-synthetically, and may include fluorescent and/or colored dyes for enhanced targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates (ADCs) use complex chemical linkers to achieve targeted delivery, then targeting capability is improved, but development complexity and time increase significantly
Solution Approach 1:
The patent divides the conjugate into distinct modular components: a polymer backbone with multiple drug attachment sites, cleavable linker modules, and optional targeting moieties. This segmentation allows independent optimization of each component and simplifies the overall development process compared to traditional single-molecule ADCs.
Solution Approach 2:
The polymer-based platform provides multi-functionality by allowing the same core structure to accommodate different drugs, linkers, and targeting moieties. This universal platform approach enables rapid development of multiple conjugates without repeating the entire optimization process for each new therapeutic.
2Ease of manufacture
If traditional ADCs use simple linker structures, then manufacturing is easier, but therapeutic index and selective delivery are insufficient
Solution Approach 1:
The patent introduces cleavable linker modules as intermediaries between the polymer backbone and drug moieties. These linkers use well-established, easily synthesized chemical structures (such as disulfide bonds, hydrazone linkages, or peptide sequences) that are simple to manufacture but provide controlled release and enhanced therapeutic index through selective cleavage at the target site.
3Reliability
If ADCs are designed with multiple biologically active moieties, then therapeutic efficacy is enhanced, but structural complexity and development difficulty increase
Solution Approach 1:
The patent merges multiple drug moieties onto a single polymer backbone structure, creating a multi-functional conjugate that delivers several therapeutic agents simultaneously or in sequence. This combining approach enhances therapeutic efficacy through synergistic effects while the modular polymer structure manages the complexity through standardized attachment points and cleavable linkers.
Data Source
AI summary
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I):or a stereoisomer, tantomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.